Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10711462
Filing Date		2004-09-20
First Named Inventor Bogd		an Radu
Art Unit		2875
Examiner Name	David	J. Makiya
Attorney Docket Numb	er	MASL-57

				U.S	.PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applican of cited Document		Releva	Columns,L ant Passage s Appear		
	1	5158353	A	1992-10-27	Kmisawa					
	2	6786614	B2	2004-09-07	Ciarrocchi, Jr					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information ;	please click the	Add button.		Add		
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Par of cited Doc	tentee or Applicant ument	Releva	,Columns,L ant Passage s Appear	nes where s or Relev	an
	1									
If you wis	Ċ	dd additional U.S. Publ	ished Ap				d button			
If you wis	Ċ	dd additional U.S. Publ	ished Ap		on information	MENTS		Remove	mpe Linae	
If you wisi Examiner Initial*	h to a	dd additional U.S. Publ Foreign Document Number ³	Countr	FOREIGN PA			e or		ant Relevant	Ι.,
Examiner	h to a	Foreign Document	Countr	FOREIGN PA	TENT DOCUM	Name of Patente Applicant of cited	e or	Remove Pages,Colu where Relev Passages o	ant Relevant	Ι.,

	Application Number		10711462
INFORMATION DIGGS COURT	Filing Date		2004-09-20
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Bogda		lan Radu
(Not for submission under 37 CFR 1.99)	Art Unit		2875
(Not los submission diluction of the 1.55)	Examiner Name	David	d J. Makrya
	Attorney Docket Numb	er	MASL-57

include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

publisher, city and/or country where published.

T5

	1	FRIEDHOFER, MICHAEL A., United States Patent and Trademark Office, Office Action Mailed June 27, 2008 in related Application Serial No. 10711,385					
	2	TRUCNG, BAO Q., United States Patent and Trademark Office, Office Action Mailed June 23, 2006 in related Application Senal No. 10/711,480					
If you wish to add additional non-patent literature document citation information please click the Add button Add							

EXAMINER SIGNATURE

Date Considered

Date Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Knd Codes of USPTO Potent Documents at year USETID CODY or METE 90164. 2 Edea of this that issued the document, by the localistic recollection of the potent potent potent potent potent and an advantage of the Emperor many process to see and under of the pathod document.

*Knot of document by the appropriate symbols as indicated on the document under WIPO Standard 511.6 if possible. *Applicant is to place a check mark here if

Examiner Cite

Initials* No

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10711462				
Filing Date		2004-09-20				
First Named Inventor Bogd		an Radu				
Art Unit		2875				
Examiner Name	David	J. Makiya				
Attorney Docket Number		MASL-57				

CERTIFICATION STATEMENT

Please see 37	7 CFR 1	.97 and	1.98 to make	the appropriat	e selection(s)	
---------------	---------	---------	--------------	----------------	----------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 137(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of Information contained in the information discusser statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) The 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) The 1.58(c) more than three months prior to the filing of the information disclosure

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/William R. Allen/	Date (YYYY-MM-DD)	2006-07-05
Name/Print	William R. Allen	Registration Number	48389

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examine; your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission or the submission of the submission or the submission or the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.